22. Barbagelata L, Masson W, Rossi E, Lee M, Lagoria J, Vilas M, et al. Cardiovascular risk stratification and appropriate use of statins in patients with chronic kidney disease according to different strategies. High Blood Press Cardiovasc Prev 29(5):435-443, Sep 2022. 23. Vega GL, Wang J, Grundy SM. Chronic kidney disease and statin eligibility. J Clin Lipidol 15(1):173-180, 2021. 24. Markossian TW, Kramer HJ, Burge NJ, Pacold IV, Leehey DJ, Huo Z, et al. Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes. Clin Kidney J 12(4):530-537, 2019. 25. Galán I, Verdalles U, García de Vinuesa M, Quiroga B, Goicoechea M, Pérez A, et al. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic. Nefrologia (Engl Ed) 38(4):379-385, 2018.
chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 5:CD007784, 2014. 18. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238-248, 2005. 19. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395-1407, 2009. 20. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111-188, 2020. 21. Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85(6):1303- 1309, 2014.
77
Rev. Arg. de Lípidos - Vol. 6 (3) 2022
Powered by FlippingBook